Medlumics, S.L.

Based in Spain, Medlumics, S. L. specializes in developing innovative medical technologies, particularly in the field of advanced imaging solutions for healthcare applications. Medlumics, S.

L. is a medical technology company focused on creating optical imaging devices for medical use. Founded in 2011 and headquartered in Madrid, Spain, the company has executed 6 deals and recently secured EUR 990,000 in venture funding on February 13, 2024, from Asabys Partners and the Center for Technological & Industrial Development. The current CEO is James Greene.

The company focuses on developing advanced medical imaging solutions, with products designed to enhance diagnostic capabilities in various healthcare settings. Their primary product, AblaView, is engineered to provide high-resolution imaging, aiding in accurate diagnosis and treatment planning for patients. Medlumics serves multiple markets worldwide, particularly in Europe and North America, addressing the growing demand for sophisticated medical imaging technologies. In the most recent fiscal year of 2017, Medlumics generated a revenue of EUR 28,258.

20. The company reported an EBITDA of -EUR 3,450,096. 50 for the year 2023, reflecting the ongoing investments in its product development and market expansion. Looking ahead, Medlumics plans to utilize the recent funding of EUR 990,000 to further develop its product, AblaView.

The company is aiming to expand its offerings and penetrate additional markets in Europe and North America by late 2024. This strategic initiative seeks to enhance the capabilities of their imaging solutions while addressing the increasing demand for advanced medical technologies.